Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RomaniaBack to Romania

Clinical trials in Oradea – page 3

105 clinical trials in Oradea, Romania across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Oradea at a glance
105
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

105 trials in Oradea

Open in trial search

Chronic obstructive pulmonary disease

Recruiting

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Major depression

Recruiting

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Transitional cell cancer of the renal pelvis and ureter

Recruiting

Study of UGN-104 (mitomycin) treatment for patients with low-grade upper tract urothelial cancer

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Urogen Pharma Ltd.

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Major depression

Recruiting

Assessment of NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
  • Sponsor:Neurocrine Biosciences Inc.

Chronic obstructive pulmonary disease

Recruiting

Study of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Gastric cancer+3

Recruiting

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Shanghai Henlius Biotech Inc.

Psychotic disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) in patients with psychosis associated with Alzheimer's disease

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Lupus nephritis

Recruiting

Study on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Colorectal cancer

Recruiting

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Other cities in Romania

The busiest research cities in the country

All 65 cities in Romania

Clinical research in Oradea

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on gastroesophageal cancer, colorectal cancer, and head and neck cancers. Studies are evaluating novel combination therapies including immunotherapy approaches for improved treatment outcomes.

  • Advanced Gastric Cancer Treatment
  • Metastatic Colorectal Cancer
  • Non-Small Cell Lung Cancer

Several trials are investigating targeted therapies and their effectiveness in specific patient populations.

02 Neurological Disorders

Comprehensive research into multiple sclerosis, epilepsy, and Alzheimer's disease. Studies are evaluating new treatments for both disease modification and symptom management.

  • Psychosis in Alzheimer's Disease
  • Drug-Resistant Epilepsy
  • Progressive Multiple Sclerosis

Focus on developing innovative therapeutic approaches for complex neurological conditions.

03 Chronic Conditions

Important research in chronic kidney disease, inflammatory bowel disease, and COPD. Trials are examining new treatment combinations and therapeutic approaches.

  • Hypertension Management
  • Crohn's Disease Therapy
  • Pulmonary Fibrosis Treatment

Studies aim to improve quality of life and disease management for patients with chronic conditions.

Back to RomaniaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.